Showing all 7 results
A 40mg BPC-157 & TB-500 formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.
A 70mg Glow formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.
Humalog Insulin (Insulin Lispro) – Rapid-Acting Mealtime Insulin for Better Blood Sugar Control Humalog Insulin (insulin lispro injection) is a trusted rapid-acting insulin designed to help adults and children with type 1 diabetes or type 2 diabetes manage high blood sugar levels effectively. Manufactured by Eli Lilly, Humalog mimics the body’s natural insulin response, starting…
NAD+ (Nicotinamide Adenine Dinucleotide) research formulation for laboratory analysis and in vitro studies only. Provided exclusively for controlled laboratory R&D applications.
A 20mg Retatrutide formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.
A 40mg Retatrutide formulation supplied in a pre-filled research device, provided exclusively for controlled laboratory R&D applications. Delivered in sealed format to support compound stability analysis, formulation studies, and delivery mechanism evaluation.
Tirzepatide 40mg Vial – Premium Dual GIP/GLP-1 Receptor Agonist Peptide for Research Unlock advanced metabolic research with Tirzepatide 40mg, a high-purity lyophilized peptide designed as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This innovative “twincretin” compound is widely studied for its potent effects on appetite regulation, glucose control, and…